The 2016 BIO CEO & Investor Conference isn’t just for biotech companies and the investment community, the conference featured a strong patient voice and focus on the patient perspective in drug development and drug delivery.
Two of the most highly-attended panel discussions were moderated by patient advocates.
On Monday, Sue Peschin, President & Chief Executive Officer, Alliance for Aging Research, led a timely panel discussion with clinical researchers and biotech CEOs around the recent positive scientific results and growth in investment levels in the fight to treat Alzheimer’s disease. Panelists included Andrew Fein, Wainwright & Co., LLC, Sharon Mates, Intra-Cellular Therapies, Mark Schoenebaum, Evercore ISI, and Martin Tolar, Alzheon.
Tuesday, Margaret Anderson, Executive Director, FasterCures, moderated a lively dialogue on the value of innovative therapies that featured diverse perspectives on what value means to patients, providers, payers, and the biotechnology industry. Panelists included Ron Cohen, MD, Acorda Therapeutics, Scott Gottlieb, American Enterprise Institute, Matthew Herper, Forbes, and Ed Silverman, STATNews.com.
In addition, five patient advocacy organizations presented to Conference attendees on the groundbreaking work they are doing in partnership with the biotech community to advance the discovery, development, and delivery of new treatments to serve the patients they represent. The Michael J. Fox Foundation, Hereditary Neuropathy Foundation, JDRF, Leukemia & Lymphoma Society, and the New York Stem Cell Foundation participated in this year’s Conference, presenting on the tremendous work their organizations are doing to advance drug development and meeting with Conference attendees to discuss the potential for future collaborations.
The presence of the patient community, as well as their contributions to the Conference program, provides a critical perspective to the conversations happening and the partnerships emerging out of #BIOCEO16.